<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089762</url>
  </required_header>
  <id_info>
    <org_study_id>AAH/02/12</org_study_id>
    <nct_id>NCT03089762</nct_id>
  </id_info>
  <brief_title>Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis</brief_title>
  <official_title>Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioheart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anupam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RegennMed Research and Therapeutics Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bioheart, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of
      fat tissue and platelet rich plasma (PRP) can be obtained from peripheral blood. Evaluated
      the safety and preliminary efficacy of administering SVF and PRP intra-articularly into
      patients with osteoarthritis grade 1 and 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2012</start_date>
  <completion_date type="Actual">December 30, 2014</completion_date>
  <primary_completion_date type="Actual">December 30, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC (Western Ontario and McMaster Universities Arthritis Index)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Six minute walk distance</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SVF and PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intra-articular injection of SVF plus PRP</intervention_name>
    <description>administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2</description>
    <arm_group_label>SVF and PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients age 50 or older who present with symptomatic primary osteoarthritis of the
             knee

          -  daily pain for the previous 3 months

          -  analgesics usage at least once a week

          -  less than 30 minutes of morning stiffness

          -  WOMAC score of â‰¤ 75 in the target knee

          -  Brandt Radiographic Grading Scale of Osteoarthritis grade 1 and 2

        Exclusion Criteria:

          -  evidence of secondary knee osteoarthritis

          -  severe osteoarthritis (Joint space width - JSW &lt; 2 mm)

          -  prior intra articular injections within the previous one year prior to inclusion

          -  patients with clinically significant systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

